SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Data From Peregrine Pharmaceuticals, Inc.'s Phase II Bavituximab Second-Line Lung Cancer Trial to be Highlighted in Late-Breaking Oral Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology